Welcome to our dedicated page for Avenue Therapeutics news (Ticker: ATXI), a resource for investors and traders seeking the latest updates and insights on Avenue Therapeutics stock.
Avenue Therapeutics reports corporate and pipeline developments as a specialty pharmaceutical company focused on therapies for rare and neurologic diseases. Its news covers licensing activity for ATX-04, a selective β2-adrenergic agonist in development for Pompe disease, and clinical-development updates for AJ201 in spinal and bulbar muscular atrophy, also known as Kennedy's disease.
Company updates also include financial results, financing and warrant activity, listing-status matters, investor-conference participation, and the completed sale of majority-owned subsidiary Baergic Bio, including rights to BAER-101. These announcements frame Avenue's portfolio around rare neuromuscular, neurologic, and related therapeutic areas.
Avenue Therapeutics, Inc. (Nasdaq: ATXI) announced the acquisition of Baergic Bio, a clinical-stage company focused on CNS disorders. This acquisition aims to enhance Avenue's portfolio with BAER-101, a selective GABA-A α2/3 receptor positive allosteric modulator in development as a treatment for various CNS conditions. The acquisition aligns with Avenue's strategy to address unmet needs in CNS therapeutics and is expected to strengthen its market position following its recent capital raise.
Avenue Therapeutics, Inc. (NASDAQ:ATXI) successfully completed a $12 million underwritten public offering, with Aegis Capital Corp. serving as the sole bookrunner on October 12, 2022. The funds raised will support the company's development of intravenous Tramadol, a dual-acting opioid currently in Phase III trials for treating post-operative acute pain. Avenue Therapeutics focuses on specialty pharmaceuticals for acute care settings and was incorporated in 2015.
Avenue Therapeutics, Inc. (Nasdaq: ATXI) announced the closing of its public offering of 3,636,365 common and pre-funded units at a price of $3.30 per unit, raising approximately $10.4 million after expenses. The capital will be used to repurchase shares held by InvaGen Pharmaceuticals Inc. and for general corporate purposes, including drug development. An additional 545,454 warrants were sold via an over-allotment option. Aegis Capital Corp. managed the offering, with all operations in compliance with SEC regulations.
Avenue Therapeutics (Nasdaq: ATXI) has priced an underwritten public offering of 3,636,365 common and pre-funded units, each at $3.30 per common unit, aiming for gross proceeds of approximately $13.8 million if the underwriter's over-allotment option is fully exercised. The offering is set to close on October 11, 2022. Proceeds will be used to repurchase shares held by InvaGen Pharmaceuticals and fund general corporate purposes, including drug development. The SEC declared the related registration statement effective on October 6, 2022.
Avenue Therapeutics (Nasdaq: ATXI) announced a 1-for-15 reverse stock split effective September 23, 2022. Approved by shareholders, the split aims to comply with Nasdaq's $1.00 minimum bid price requirement. Post-split, outstanding shares will decrease from approximately 22.7 million to about 1.5 million. Additionally, Avenue discussed regulatory updates regarding its intravenous Tramadol product, receiving positive feedback from the FDA on a proposed safety study design to mitigate risks associated with opioid stacking. The company plans to submit a detailed protocol based on FDA suggestions.
Avenue Therapeutics (NASDAQ: ATXI) announced the outcome of the FDA joint meeting concerning its IV tramadol development for acute pain management. The Advisory Committee voted 8-14 against whether the benefits of IV tramadol outweigh its risks in inpatient settings. The FDA requires this input for a decision on Avenue's formal dispute resolution request, expected within 30 days. Avenue aims to provide an alternative to conventional opioids for acute pain relief in the U.S.
Avenue Therapeutics announced that the FDA Advisory Committee will review the New Drug Application for IV tramadol on February 15, 2022. The meeting will involve the Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management Committees. This review is crucial as it influences the Office of New Drugs' decision regarding Avenue's formal dispute resolution request. Trading of Avenue's stock on NASDAQ has been suspended pending this event.
Avenue Therapeutics has successfully completed a $2 million public offering of common stock, with Aegis Capital Corp. acting as the sole bookrunner. The funds raised will support the company’s ongoing development of IV tramadol, an alternative aimed at reducing opioid use for patients with acute pain in the U.S. Avenue Therapeutics is headquartered in New York City and is focused on innovative solutions for pain management.
Avenue Therapeutics (NASDAQ: ATXI) has successfully closed its public offering of 1,910,100 shares of common stock at a price of $1.07, raising approximately $2.0 million in gross proceeds. Aegis Capital Corp. acted as the sole book-running manager for this offering and has a 45-day option to purchase an additional 286,430 shares to cover over-allotments. The registration statement for the offering was declared effective by the SEC on December 10, 2021. Avenue Therapeutics aims to develop IV tramadol as a potential alternative to conventional opioids for acute pain management.
Avenue Therapeutics (NASDAQ: ATXI) announced a public offering priced at $1.07 per share, aiming for gross proceeds of approximately $2.0 million. The offering will consist of 1,910,100 shares and is set to close on December 15, 2021, pending typical closing conditions. With a 45-day underwriters' option, the total could reach up to $2.3 million. The net proceeds will support working capital and corporate purposes. Avenue specializes in developing intravenous tramadol as an alternative to opioids for acute pain management in the U.S.